Topoisomerase 1

  • Yves Pommier
Reference work entry


Humans have two type IB topoisomerases (Top1 and Top1mt), and TOP1 is one of the six vertebrate topoisomerase genes (TOP1, TOP1MT, TOP2A, TOP2B, TOP3A and TOP3B). Topoisomerase activity is essential for transcription and a replication as DNA is an extremely long polymer (up to 2 meters in the nucleus of human cell) that readily forms loops, supercoils, knots and catenanes. Top1 autoantibodies are commonly found in the blood of patients with autoimmune diseases (Scleroderma pigmentosum). Top1 is generally overexpressed in cancer cells and the target of widely used camptothecin derivatives. Novel indenoisoquinoline Top1 inhibitors and targeted delivery Top1 inhibitors are in clinical trials.


Topoisomerase Chemotherapy Autoimmune disorders Camptothecin Topotecan Irinotecan Onivyle 


  1. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105:9053–9058.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Champoux JJ, Dulbecco R. An activity from mammalian cells that untwists superhelical DNA – a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc Natl Acad Sci USA. 1972;69:143–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. D’Arpa P, et al. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA. 1988;85:2543–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Douarre C, et al. Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. PLoS One. 2012;7:e41094. doi:10.1371/journal.pone.0041094.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Giovanella BC, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046–8.CrossRefPubMedGoogle Scholar
  6. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873–8.PubMedGoogle Scholar
  7. Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM, Zhang H, Pommier Y. Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of Doxorubicin cardiotoxicity. Clin Cancer Res. 2014;20:4873–4881.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Khiati S, Baechler SA, Factor VM, Zhang H, Huang SN, Dalla Rosa I, Sourbier C, Neckers L, Thorgeirsson SS, Pommier Y. Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. Proc Natl Acad Sci USA. 2015;112:11282–11287.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Kim N, et al. Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science. 2011;332:1561–4.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Miao ZH, et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 2007;67:8752–61.CrossRefPubMedGoogle Scholar
  11. Pfister TD, et al. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther. 2009;8:1878–84. doi:10.1158/1535-7163.mct-09-0016.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802.CrossRefPubMedGoogle Scholar
  13. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009;109:2894–902.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Pommier Y. DNA Topoisomerases and Cancer, New York, Dordrecht, Heidelberg, London: Springer & Humana Press; 2012.CrossRefGoogle Scholar
  15. Pommier Y, Jenkins J, Kohlhagen G, Leteurtre F. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutat Res. 1995;337:135–45.CrossRefPubMedGoogle Scholar
  16. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33.CrossRefPubMedGoogle Scholar
  17. Seol Y, Zhang H, Pommier Y, Neuman KC. A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. Proc Natl Acad Sci USA. 2012. doi:10.1073/pnas.1206480109.PubMedPubMedCentralGoogle Scholar
  18. Sordet O, Khan QA, Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle. 2004;3:1095–7.CrossRefPubMedGoogle Scholar
  19. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol. 2008;75:1262–71.CrossRefPubMedGoogle Scholar
  20. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic – thirteenth Bruce F Cain Memorial Award lecture. Cancer Res. 1995;55:753–60.PubMedGoogle Scholar
  21. Wang W, et al. Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing. Nucleic Acids Res. 2011;39:44–58.CrossRefPubMedGoogle Scholar
  22. Zhang H, et al. Human mitochondrial topoisomerase I. Proc Natl Acad Sci USA. 2001;98:10608–13.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Laboratory of Molecular PharmacologyCenter for Cancer Research, National Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations